Xencor is shifting from licensing optionality toward a broader portfolio of in-house assets across oncology and immunology.
Austin, Texas, July 6th, 2026, FinanceWireVERAXA Biotech (NASDAQ: VRXA) provided a corporate and pipeline update ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results